# Caplin Point Laboratories share price today (Caplin Point Laboratories Ltd, NSE: CAPLIPOINT)

> Caplin Point Laboratories share price today: ₹2,416.10 at the NSE close on 4 November 2026, up 25.0% in a year. Caplin Point Laboratories (NSE: CAPLIPOINT) is worth ₹18,362 crore, trades at a P/E of 27.6 and has closed between ₹1,558.40 and ₹2,845.20 over the past 52 weeks. > Caplin Point Laboratories Ltd grows steadily. It earns returns above 15% with few surprises. CAPLIPOINT · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹2,416.10 (+25.0% in a year)
- P/E: 27.6× (higher than 69% of the last 11 years)
- Revenue (Jun 2026): ₹610 Cr (+19.6% on a year ago)
- Profit (Jun 2026): ₹179 Cr (+18.5% on a year ago)
- Operating margin: 35.0% (flat on a year ago)
- ROCE: 24%, FY26
- ROIC: 21.6%, against a 12.0% cost of capital: +9.6 points

Biggest thing to watch: the P/E is higher than 69% of its own history, so the multiple has already done part of the work. ## What is the Caplin Point Laboratories share price today? Caplin Point Laboratories Ltd's share price was ₹2,416.10 at the close on 4 November 2026. It has been rising for 21 weeks. That is 5.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,558 and ₹2,845, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +1,077% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Caplin Point Laboratories this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and highest quarterly profit in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹610 crore, +19.6% on a year earlier. Why: The latest rise came from US sales nearly tripling. Next results: check whether the new sterile lines start adding sales after approvals. From the earnings call on 12 Aug 2026. 2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter profit was ₹179 crore, +18.5% on a year earlier. Why: Profit rose because running costs took a smaller share of sales. Next results: check whether gross margin, sales minus direct product costs, stays near 60% as product mix changes. From the earnings call on 12 Aug 2026. 3. Highest quarterly profit in 15 quarters Profit of ₹179 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Caplin Point Laboratories' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Caplin Point Laboratories reported revenue of ₹610 crore, up 19.6% from ₹510 crore a year earlier, and a profit of ₹179 crore, up 18.5% from ₹151 crore. ### Caplin Point Laboratories results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹610 crore | ₹510 crore | +19.6% |
| Profit | ₹179 crore | ₹151 crore | +18.5% |
| Earnings per share | ₹23.27 | ₹20.10 | +15.8% |
| Operating margin | 35.0% | 35.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Caplin Point Laboratories' management discussed these results on a call held on 12 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Caplin Point Laboratories share price history? Caplin Point Laboratories closed at ₹2,416.10 on 4 November 2026, up 25.0% from ₹1,932.50 a year earlier (7 November 2025) and up 186.9% over five years. Its highest weekly close since March 2016 was ₹2,845.20 on 28 September 2026. ### Caplin Point Laboratories share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹2,324.85 | +3.9% |
| 1 month ago · 1 Oct 2026 | ₹2,632.35 | −8.2% |
| 6 months ago · 8 May 2026 | ₹1,856.30 | +30.2% |
| 1 year ago · 7 Nov 2025 | ₹1,932.50 | +25.0% |
| 3 years ago · 3 Nov 2023 | ₹1,053.15 | +129.4% |
| 5 years ago · 4 Nov 2021 | ₹842.25 | +186.9% |
| 10 years ago · 4 Nov 2016 | ₹364.35 | +563.1% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹205.33 | +1,076.7% |
| Highest weekly close since March 2016, also the 52-week high · 28 Sep 2026 | ₹2,845.20 | −15.1% |
| Lowest weekly close since March 2016 · 6 May 2016 | ₹188.66 | +1,180.7% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹1,558.40 | +55.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Caplin Point Laboratories? 4 Nov 2026: Caplin Point Laboratories closed at ₹2,416.10, up 3.9% on the week and down 8.2% on the month. 18 Sep 2026: ex-date for a dividend of ₹4 a share. ### Earlier

- Our read, 22 Aug 2026: A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet, earnings growing steadily while the sterile injectable ramp is the next profit multiplier. - 12 Aug 2026: Caplin Point Laboratories held its results call for April to June 2026. Management guided: Gross margin expected around 60% through the year. - Results for April to June 2026: Revenue up 19.6% and profit up 18.5% on a year earlier. - 29 May 2026: ex-date for an interim dividend of ₹4 a share, record date 30 May 2026. ### Our read of the business

Caplin Point has grown profit from 251 crore in FY21 to 650 crore in FY26 with zero debt, funding a 1,000 crore capital spending cycle from operating cash. The US sterile business nearly tripled its own-label revenue year-on-year in April to June 2026, proving the ramp is real. April to June 2026: 20% revenue growth, 19% profit growth, operating margin stable at 35%, solid delivery against elevated expectations. (Our read after the April to June 2026 results, written 22 August 2026.)

## What dividend does Caplin Point Laboratories pay? Caplin Point Laboratories paid ₹8 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.33% at the ₹2,416.10 close on 4 November 2026. The last was a dividend of ₹4 a share, ex-date 18 September 2026. ### Caplin Point Laboratories dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 18 Sep 2026 | ₹4 | Dividend | same day |
| 29 May 2026 | ₹4 | Interim | 30 May 2026 |
| 12 Sep 2025 | ₹3 | Dividend | same day |
| 30 May 2025 | ₹3 | Interim | same day |
| 23 Sep 2024 | ₹2.50 | Dividend | same day |
| 31 May 2024 | ₹2.50 | Interim | same day |
| 14 Sep 2023 | ₹2.50 | Dividend | n/a |
| 9 Jun 2023 | ₹2 | Interim | same day |
| 21 Sep 2022 | ₹2 | Dividend | n/a |
| 23 May 2022 | ₹2 | Interim | 24 May 2022 |
| 20 Sep 2021 | ₹1.50 | Dividend | n/a |
| 18 May 2021 | ₹1.50 | Interim | 19 May 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Caplin Point Laboratories Ltd paid out 9% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Caplin Point Laboratories management say on the latest results call? On the call for April to June 2026, held on 12 August 2026, Caplin Point Laboratories' management guided: Gross margin expected around 60% through the year. > “Our current challenge is not in the form of dearth of orders but lack of capacities in our two major factories which is CP1 in Pondicherry and the CSL in Gummidipoondi.”
> CC Partheban, Chairman, on the call for April to June 2026

### What management guided

- FY27 profit margin commitment at 25%. - Cash flow expected to improve from July to September 2026 as inventory additions normalize; government-supply receivables expected by October to December 2026. - Sterile rollout: Line 7 in 6-7 months; five Phase 3 lines by this time next year; 13 lines visible including oncology; transferred products need 9-10 months for commercial start; three-four more lines potentially by 2029+. - Amaris expansion to 120 beds for internal BE studies. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2767/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 12 August 2026.)

## What could change the Caplin Point Laboratories story? What are the risks? Sterile line commissioning slips by more than three quarters, product transfers require 9-10 months for supplements and stability batches before commercial contribution, so a capacity delay compounds into a revenue lag. ### Each change stops working if

- : Sterile line commissioning slips by more than three quarters, product transfers require 9-10 months for supplements and stability batches before commercial contribution, so a capacity delay compounds into a revenue lag. - : LATAM tender participation dries up and private-market penetration stalls because Mexico local manufacturing is not yet economical, removing both the tender and the private-market growth legs simultaneously. - : Rest-of-world profit before tax margin keeps falling from its current 33%, a continued decline there combined with higher depreciation from new line capitalisations could offset the operating leverage on headline operating margin. - : A large unplanned acquisition significantly depletes the liquid buffer, changing the risk profile from self-funded to leveraged. ### The main risks

- : April to June 2026 operating cash flow/profit of 0.53, the weakest quarterly conversion in recent memory, driven by inventory build and government receivables. ⚠ estimate
- : Rest-of-world profit before tax margin fell from 37.5% to approximately 33% in April to June 2026, generic mix and added marketing costs compressing the LATAM core. ⚠ estimate
- : ROCE structural decline from 45% in FY19 to 25% in FY26, acceptable in a manufacturing scale-up but may compress further before CSL matures. ⚠ estimate

(Our read after the April to June 2026 results, written 22 August 2026.)

## What to watch in Caplin Point Laboratories' next results? When Caplin Point Laboratories reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Rest-of-world profit before tax margin to stabilize or improve - check for continued generic-mix and marketing-cost pressure. - What to check (from the call)
- Rest-of-world profit before tax margin to stabilize or improve - check for continued generic-mix and marketing-cost pressure. - Government receivables to convert and CFO to recover as inventory additions normalize. - El Salvador supplementary tender decision and delivery conversion to revenue. - Sterile commissioning and product-transfer approvals to begin converting capacity into commercial contribution. ## Which stock lists is Caplin Point Laboratories on? Caplin Point Laboratories is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 378](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 18364.894951840386](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Caplin Point Laboratories profitable? Caplin Point Laboratories Ltd earned ₹179 Cr of net profit in the Jun 2026 quarter, +18.5% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹650 Cr. Over 10 years profit has grown 30.3% a year on average. That is 29.3% of the quarter's revenue. The same quarter a year earlier earned ₹151 Cr. For the full year, FY26 profit was ₹650 Cr (+20.1% on the year before). Why profit moved: revenue changed +19.6% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +19.6% and revenue +15.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported. FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much revenue does Caplin Point Laboratories make, and is it growing? Caplin Point Laboratories Ltd reported ₹610 Cr of revenue in the Jun 2026 quarter, +19.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 24.8% a year on average. The last full year, FY26, came in at ₹2,187 Cr. Why this happened. CSL own-label revenue grew from 14.4 crore to 43.1 crore year-on-year in Q1 FY27, tracking ahead of the 200-crore FY27 full-year goal. The US business grew 26% overall. CSL has 39 of 60-plus approved ANDAs and has 40-plus products in pipeline spanning pre-filled syringes, ophthalmic suspensions and other sterile forms. New lines are commissioning over the next 6-18 months, each unlocking additional ANDA commercial capacity. The last four reported quarters add to ₹2,287 Cr. FY26 revenue was ₹2,187 Cr, +12.9% on the year before. Recent pace: the last four quarters grew +15.0% on average, against 24.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +15.0%, against +14.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +19.6%, against +18.6% a year (stabilising). FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported. FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Caplin Point Laboratories keep? Caplin Point Laboratories Ltd's operating margin was 35.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 21.0% and 36.0%. The latest quarter is within that range. Why this happened. OPM has run at 34-35% for six consecutive quarters without dipping below 33%. In Q1 FY27, the EBITDA margin expanded as the operating-expense ratio fell from 25.7% to 23.6% despite gross margin moving with mix. Personnel costs from the hiring phase are already embedded; each incremental revenue rupee contributes at a high marginal rate. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed −1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported. FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## Is Caplin Point Laboratories' profit turning into cash? Over the last 3 years, 77% of Caplin Point Laboratories Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹523 Cr of operating cash against ₹650 Cr of profit. After ₹197 Cr of spending on assets, ₹326 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 77% of profit came in as cash: the cash cycle got 28 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 28 days longer. The next section looks at where the cash is stuck. ## Where does Caplin Point Laboratories' cash go? Caplin Point Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 194 days in FY26, up from 166 days in FY21. It spent ₹505 Cr on assets over the last 3 years. Customers take 138 days to pay, and stock sits for 181 days on average. Why this happened. Chile entered with 135 product registrations and 10 million dollars of orders secured for 18 months. Mexico swept all 8 products in a 2-year government tender, has 25 registrations, and has a 4 million dollar near-term sales goal; local manufacturing is under evaluation. The El Salvador supplementary tender is pending decision and could add 10-15% of the original tender volume. At FY26 sales of ₹2,187 Cr, each day of that cycle ties up about ₹6.0 Cr, so roughly ₹1,162 Cr is tied up in the business at any time. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 181 days. Customers pay about 138 days after that. Suppliers are paid at 125 days. Together that makes the 194-day cycle. Spending on assets: ₹505 Cr over the last 3 years, against ₹192 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹234 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Caplin Point Laboratories' P/E ratio, and how does it compare with its own history? Caplin Point Laboratories Ltd's P/E is 27.6×, in the middle of its own history: higher than 69% of past readings. Its usual P/E (the middle reading) is 22.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +19.6% while the price moved +25.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +23.5% a year; about +20.6% a year came from earnings growth and about +2.9 percentage points from the multiple (the market paying more); over 10 years the price moved +20.8% a year; about +25.2% a year came from earnings growth and about −4.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Caplin Point Laboratories share price assume? Worked out from its price on 24 August 2026, Caplin Point Laboratories Ltd's share price assumed profit growth of about 16.6% a year. Over the past 10 years its profit actually grew 30.3% a year. Today its P/E is 27.6×, higher than 69% of its own last 11 years. This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Caplin Point Laboratories business getting better or worse? Caplin Point Laboratories Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 25.7%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the Caplin Point Laboratories story, and has it been checked? Caplin Point Laboratories Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file. Our read, 22 August 2026. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet, earnings growing steadily while the sterile injectable ramp is the next PAT multiplier. From the numbers. The stock has…

From the price. Price stage 2, week 21, above its 200-day line, relative strength falling. From the research. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet, earnings growing steadily while the sterile injectable ramp is the next PAT multiplier. Where they disagree. The stock has run 4.3x over 36-48 months and is within 2% of its peak. What is proven. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet, earnings growing steadily while the sterile injectable ramp is the next PAT multiplier. What is not proven yet. What would change our mind. What the company does. Caplin Point has grown PAT from 251 crore in FY21 to 650 crore in FY26 with zero debt, funding a 1,000 crore capex cycle from operating cash. The US sterile business nearly tripled its own-label revenue year-on-year in Q1 FY27, proving the ramp is real. Sources: our stock research file (22 August 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Caplin Point Laboratories management deliver what it promised? What Caplin Point Laboratories Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Sterile Capacity Timeline Extended · 12 August 2026. The November 2025 and February 2026 calls presented 12 to 15 injectable lines as coming online within the next two years. In the August 2026 call, management said only 13 lines had visibility and that the final three to four lines could be activated in 2029 and beyond, materially extending the previously indicated timeline without explaining the change. Repeated Upward Revision of Injectable Lines Goal · 14 May 2026. Across all three consecutive calls, management increased the stated total injectable lines goal without any explanation. The figure rose from 12 lines in Nov 2025, to 14-15 lines in Feb 2026, to 17 lines in May 2026 - a 42% increase over six months - while the stated completion window also widened from two years to two to three years. Shareholders modeling the US capacity buildout and revenue ramp have no stable anchor as the goal has shifted materially with each call. Capex Completion Timeline Extended Without Explanation · 14 May 2026. In the Feb 2026 call, the CFO stated the remaining approximately 615 crores of the 1,000 crore capex plan would be spent within the next 12 to 18 months, implying completion by mid-to-late 2027. In the May 2026 call, the remaining balance of approximately 510 crores is now guided to take 18 to 24 months, pushing implied completion to late 2027 or mid-2028. The implied spending rate slowed materially across the two calls with no explanation provided, directly delaying when new capacity becomes operational and revenue-generating. Receivables Days Commitment Missed and Goal Quietly Expanded · 14 May 2026. In the Feb 2026 call, the CFO explicitly committed to returning receivables days to the stated 120-day benchmark by March 2026, or at latest June 2026. The May 2026 call reveals Q4 FY26 receivables at 136 days, or 125 days after adjusting for FCTR - both figures above the committed level by a meaningful margin. More significantly, management has now widened the stated acceptable range to 130 days going forward without acknowledging the prior commitment was missed, effectively shifting the benchmark post-facto. Every quote above is taken word for word from the company’s own earnings calls. ## What is Caplin Point Laboratories management's track record? Self-funded ~1,000cr capital spending at zero leverage off 523cr operating cash flow. ### Regulatory and governance record

Only routine statutory insider-trade disclosures; no name-specific SEBI/CBI/ED action (lone SEBI item is the unrelated HDFC merger case). 0% Promoter shares pledged

Sources:

- [screener.in](https://www.screener.in/company/CAPLIPOINT/)
- [m.economictimes.com](https://m.economictimes.com/markets/stocks/news/sebi-slaps-rs-10-lakh-fine-on-entity-for-insider-trading-during-hdfc-hdfc-bank-merger/articleshow/122978098.cms)
- [choiceindia.com](https://choiceindia.com)

(Checked 30 June 2026.)

## How much does Caplin Point Laboratories earn on its capital? Caplin Point Laboratories Ltd earned a ROCE of 24% in FY26. Its return on capital used (ROIC) is 9.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 29.7% net margin and 0.54× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 29.7% net margin × 0.54× asset turnover × 1.20× leverage (assets divided by equity) ≈ 19.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 21.6% − 12.0% = +9.6 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 21.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 23.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Caplin Point Laboratories have too much debt? Caplin Point Laboratories Ltd has total debt of ₹5.0 Cr against shareholder equity of ₹3,631 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. Why this happened. The company has 1,503 crore in cash and cash equivalents plus 2,875 crore total liquid assets against zero bank debt. Residual capex of approximately 510 crore is fully funded. A Mexico distribution acquisition and the Amaris Clinical expansion are both internally funded options that could accelerate the thesis without dilution. ## What is the Caplin Point Laboratories shareholding pattern? Foreign institutions raised their stake in Caplin Point Laboratories Ltd by 2.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 5.7% of the company. Domestic institutions moved +0.4 points over the same period, to 2.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +2.0 points over 8 quarters, to 5.7%; Domestic institutions: +0.4 points over 8 quarters, to 2.2%; Promoters: +0.0 points over 8 quarters, to 70.6%. Why the owners changed: foreign institutions drove it (+2.0 points). They raised their stake step by step. ## How far is Caplin Point Laboratories from balance-sheet trouble? For Caplin Point Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Caplin Point Laboratories rank in its industry? 54.3 out of 100, rank 19 of 44 in Pharma - Formulators, with 96% of the evidence available. Caplin Point Laboratories Ltd scores 54.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 19. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.7 + 17.6 + 10.1 + 7.9 = 54.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Caplin Point Laboratories compared with? Caplin Point Laboratories ranks 19 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 54.3 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. Caplin Point Laboratories Ltd this page CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.7/35 · Revenue 15% · Profit 19.6% · Operating margin change 0 points · 88% evidence Capital efficiency 17.6/25 · ROCE 24.2% · Operating margin 35% · 100% evidence Valuation 10.1/20 · P/E 26.6× · PEG 1.52 · 100% evidence Relative strength 7.9/20 · Lead over its industry -6.4% · Lead over NIFTY 500 15.5% · 1 year 14.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 18.7 + 17.6 + 10.1 + 7.9 = 54.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Caplin Point Laboratories in size? Caplin Point Laboratories is the 18th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Emcure Pharmaceuticals, Wockhardt and Rubicon Research. Just below it: ERIS Lifesciences, Alembic Pharmaceuticals and Natco Pharma. ### Pharma - Formulators companies close in size

1. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) ₹35,510 crore
2. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) ₹30,895 crore
3. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) ₹26,660 crore
4. Caplin Point Laboratories Ltd ₹17,677 crore
5. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ₹16,044 crore
6. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹15,683 crore
7. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) ₹15,348 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [EIH Ltd](https://www.sectoralpha.in/stocks/eih-ltd) ₹17,907 crore · Hotels
2. [Pine Labs Ltd](https://www.sectoralpha.in/stocks/pine-labs-ltd) ₹17,697 crore · E-Commerce - Platform - Utility
3. Caplin Point Laboratories Ltd ₹17,677 crore
4. [Chalet Hotels Ltd](https://www.sectoralpha.in/stocks/chalet-hotels-ltd) ₹17,643 crore · Hotels
5. [Finolex Cables Ltd](https://www.sectoralpha.in/stocks/finolex-cables-ltd) ₹17,435 crore · Cables - Telecom

## What else do people ask about Caplin Point Laboratories? ### What is Caplin Point Laboratories's share price today? Caplin Point Laboratories Ltd's share price is ₹2,416.10, +25.0% over the past year. The whole company is worth ₹18,362 Cr on the market. In the last 52 weeks it traded between ₹1,558 to ₹2,845; today it is 67% of the way up from the low, 5.2% above its 200-day average (as of 4 November 2026). ### What were Caplin Point Laboratories's latest quarterly results? Caplin Point Laboratories Ltd reported revenue of ₹610 Cr and net profit of ₹179 Cr for the Jun 2026 quarter. Revenue rose 19.6% and profit rose 18.5% compared with a year earlier. Earnings per share were ₹23.27. The operating margin was 35.0%, 0.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Caplin Point Laboratories's market cap? Caplin Point Laboratories Ltd's market capitalisation is ₹18,362 Cr at a share price of ₹2,416.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Caplin Point Laboratories performing? Caplin Point Laboratories Ltd's share price has been rising for 21 weeks. In its latest quarter, revenue rose 19.6% and profit rose 18.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 4 November 2026). ### Will Caplin Point Laboratories's share price go up? This page does not forecast Caplin Point Laboratories Ltd's share price. What it shows instead: the share price is ₹2,416.10, and it has been rising for 21 weeks. Its P/E of 27.6× is higher than 69% of its own last 11 years (as of 4 November 2026). ### Does Caplin Point Laboratories have too much debt? No, Caplin Point Laboratories Ltd has little debt: its debt is 0.07× its equity, and its operating profit is more than 100 times its interest bill. FY26 borrowings were ₹221 Cr against equity of ₹3,370 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Caplin Point Laboratories in its business cycle? Caplin Point Laboratories Ltd's FY26 operating margin was 35.0%, against a 13-year range of 21.0% to 36.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 35.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Caplin Point Laboratories story? Biggest thing to watch: the P/E is higher than 69% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Caplin Point Laboratories a stock worth studying right now? What the numbers show: Caplin Point Laboratories Ltd grows steadily. It earns returns above 15% with few surprises. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Caplin Point Laboratories share price forecast for 2026? What management itself guided: Gross margin expected around 60% through the year. What would change the story: Sterile line commissioning slips by more than three quarters, product transfers require 9-10 months for supplements and stability batches before commercial contribution, so a capacity delay compounds into a revenue lag. ### Where does this page get Caplin Point Laboratories' management information? From Caplin Point Laboratories' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.